Point Biopharma Global Inc logo

Point Biopharma Global Inc Share Price (NASDAQ: PNT)

▲

-13.71

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 17 Nov 2023

Check the interactive Point Biopharma Global Inc Stock chart to analyse performance

Point Biopharma Global Inc Key Stats

Check Point Biopharma Global Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$13.71
Open
$13.7
Market Capitalization
$1.4B
Today's Volume
$1.6M
Revenue TTM
$243.7M
EBITDA
$110.4M
Earnings Per Share (EPS)
$1.1
PE Ratio
12.12
Dividend Yield
0.0%
Profit Margin
39.62%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
26.33%

Global Institutional Holdings in Point Biopharma Global Inc

  • Name

    Holdings %

  • Bvf Inc

    9.99%

  • BlackRock Inc

    6.00%

  • Vanguard Group Inc

    4.21%

  • State Street Corporation

    3.21%

  • Great Point Partners LLC

    2.84%

  • Deep Track Capital, LP

    2.63%

Analyst Recommendation on Point Biopharma Global Inc Stock

Rating
Trend

Hold

    43%Buy

    56%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Point Biopharma Global Inc(by analysts ranked 0 to 5 stars)

About Point Biopharma Global Inc

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Organization
Point Biopharma Global Inc
Employees
129
CEO
Mr. Allan Charles Silber
Industry
Miscellaneous

Important FAQs about investing in PNT Stock from India :

What is Point Biopharma Global Inc share price today?

Point Biopharma Global Inc share price today is as on . Point Biopharma Global Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Point Biopharma Global Inc share?

Point Biopharma Global Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Point Biopharma Global Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Point Biopharma Global Inc Stock (PNT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Point Biopharma Global Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Point Biopharma Global Inc Shares .

What is the minimum amount required to buy Point Biopharma Global Inc Stock (PNT) from India?

Indian investors can start investing in Point Biopharma Global Inc (PNT) shares with as little as ₹88.1212 or $1 (as of September 19, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.21 in Point Biopharma Global Inc stock (as per the Rupee-Dollar exchange rate as on September 19, 2025). Learn more about fractional shares .

What are the returns that Point Biopharma Global Inc has given to Indian investors in the last 5 years?

Point Biopharma Global Inc stock has given 0.0% share price returns and 19.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?